UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 14, 2016
OSIRIS THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
|
Maryland |
|
001-32966 |
|
71-0881115 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
7015 Albert Einstein Drive, Columbia, Maryland |
|
21046 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (443) 545-1800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Termination of Chief Medical Officer
On April 12, 2016, the Company terminated its Chief Medical Officer, Jon Hopper, BSc., MB ChB, FRCSEd., MBA (Health Executive). Mr. Hopper’s responsibilities will be assumed by others with the Company’s management team, including the Company’s Director of Regulatory Affairs and the Company’s Chief Scientific Officer. The Company has undertaken a search for a potential replacement Chief Medical Officer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
OSIRIS THERAPEUTICS, INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ GREGORY I. LAW |
|
|
|
Gregory I. Law |
|
|
|
Chief Financial Officer |
Date: April 14, 2016